China Pharma Holdings, Inc. (CPHI) stock
Close on Nov 11, 2026Market cap $23.37MP/E –Yield –
China Pharma Holdings, Inc. saw revenue fall 11.0% to $3.91M over the twelve months to Jun 30, 2026. Free cash flow was $88.94K. At the latest close the market valued the company at $23.37M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $23.37M
- P/E ratio
- –
- Price to sales
- 5.97
- Price to book
- 0.65
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.91M
- Net income
- -$4.47M
- EPS, diluted
- -$0.43
- Free cash flow
- $88.94K
- Book value per share
- $0.89
- Diluted shares
- 41M
Trading
- Previous close
- $0.55
- Open
- $0.55
- Day's range
- $0.50 – $0.57
- Volume
- 115,123
- Average volume (20 days)
- 152,483
- Beta (5 years)
- 0.88
- 52-week range
- $0.38 – $19.19
- RSI (14 days)
- 36.2
- Volatility (1 year)
- 807.8%
- Relative volume
- 0.03×
- WACC
- 8.9%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CPHI | S&P 500 | Difference | CPHI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.6% | -2.4% | −35.2 pts | ||
| 3 months | -51.9% | -1.2% | −50.8 pts | ||
| Year to date | -55.1% | +12.3% | −67.4 pts | ||
| 1 year | -65.3% | +12.4% | −77.7 pts | ||
| 3 years | -87.8% | +78.8% | −166.6 pts | -50.5% | +21.4% |
| 5 years | -99.8% | +75.2% | −175.0 pts | -72.0% | +11.9% |
| 10 years | -99.5% | +311.1% | −410.7 pts | -41.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases China Pharma filed with the SEC as exhibits to Form 8-K or 6-K
About China Pharma
Pharmaceutical Preparations
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products, comprehensive healthcare items, and protective equipment. Operating through its subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd., the enterprise provides treatments for high-incidence and high-mortality conditions in China, including cardiovascular, central nervous system, infectious, and digestive disorders. Its offerings encompass basic generic pharmaceuticals, first-to-market generic formulations, and modern Traditional Chinese Medicines produced in formats such as tablets, capsules, injectables, and oral solutions. China Pharma distributes its prescription and healthcare products to hospitals and retail pharmacies via qualified provincial and municipal logistics distributors.
Company profile, executives and historyChina Pharma stock: common questions
What is China Pharma's stock price?
CPHI closed at $0.54 on Nov 11, 2026, down 1.43% on the day. Over the past 52 weeks it traded between $0.38 and $19.19.
What is China Pharma's market cap?
China Pharma was worth $23.37M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CPHI's P/E ratio?
China Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.43), so it has no meaningful P/E ratio.
How much revenue does China Pharma make?
China Pharma reported revenue of $3.91M for the twelve months to Jun 30, 2026, down 11.0% from a year earlier.
Does China Pharma pay a dividend?
No. China Pharma has not paid a cash dividend over the last twelve months.
How has CPHI stock performed over the past year?
Including dividends, CPHI returned -65.3% over the past year, against +12.4% for the S&P 500.
How many CPHI shares are sold short?
0M shares were sold short at the latest FINRA report, 0.21% of the float, or 1.0 days of average trading volume.
Who are China Pharma's competitors?
Companies most similar to China Pharma by business, industry and size include SXTC, PMHS, PTCHF, ANL, KYNB.
See a number that looks wrong?